You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

platinum resistance

Showing 1 - 25 of 9,777
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)

Not yet recruiting
  • Ovarian Cancer
  • Maywood, Illinois
    Loyola University Medical Center
Aug 1, 2023

Efficacy and Safety Trial in Zhejiang (Arsenic trioxide Tablet +Fuzuloparib Capsules)

Recruiting
  • Efficacy and Safety
  • Arsenic trioxide Tablet +Fuzuloparib Capsules
  • Zhejiang, Hangzhou, China
    Women's Hospital School Of Medicine Zhejiang University
Jan 23, 2022

Epithelial Ovarian Cancer Trial in Toulouse (Patients treated with platinum based-chemo)

Recruiting
  • Epithelial Ovarian Cancer
  • Patients treated with platinum based-chemotherapy
  • Toulouse, France
    Institut Universitaire du Cancer de Toulouse - Oncopole
Aug 2, 2022

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma Trial in

Unknown status
  • Platinum-resistant Ovarian Cancer
  • +3 more
  • PHI-101 administration
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Jan 16, 2021

Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation Trial in Changsha (Gemcitabine platinum combined with erlotinib)

Recruiting
  • Carcinoma, Non-Small Cell Lung
  • EGFR Gene Mutation
  • Gemcitabine platinum combined with erlotinib
  • Changsha, Hunan, China
    Hunan Province Tumor Hospital
Feb 28, 2022

A Training Set for the HRD Model in EOC

Recruiting
  • Epithelial Ovarian Cancer
  • +5 more
  • Homologous recombination deficiency model
  • Beijing, Beijing, China
    Lei Li
Dec 2, 2020

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023

Carcinoma, Small Cell Lung Trial in United States (RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide)

Active, not recruiting
  • Carcinoma, Small Cell Lung
  • RRx-001 + eLOOP Device
  • Cisplatin/carboplatin plus etoposide
  • Tampa, Florida
  • +5 more
Oct 3, 2022

Carcinoma, Small Cell Lung Trial in United States (RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide)

Terminated
  • Carcinoma, Small Cell Lung
  • RRx-001 + eLOOP Device
  • Cisplatin/carboplatin plus etoposide
  • Denver, Colorado
  • +17 more
Sep 30, 2022

The Registry of Genetic Alterations of Taiwan Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
    • Kaohsiung, Taiwan
    • +7 more
    Nov 8, 2023

    Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemo, Platinum Sensitive Trial in China,

    Active, not recruiting
    • Relapsed Ovarian Cancer
    • +2 more
    • Olaparib 300mg tablets
    • Beijing, China
    • +24 more
    Dec 5, 2022

    Gynecologic Cancer, Ovarian Cancer, High Grade Serous Carcinoma Trial in Ljubljana (Carboplatin)

    Recruiting
    • Gynecologic Cancer
    • +3 more
    • Ljubljana, Slovenia
    • +1 more
    Aug 6, 2022

    Large Cell Neuroendocrine Carcinoma of the Lung Trial in Germany (Atezolizumab)

    Recruiting
    • Large Cell Neuroendocrine Carcinoma of the Lung
    • Berlin, Germany
    • +13 more
    Jul 20, 2022

    Ovarian Cancer Trial in Lexington (Lapatinib and Paclitaxel)

    Recruiting
    • Ovarian Cancer
    • Lapatinib and Paclitaxel
    • Lexington, Kentucky
      Markey Cancer Center
    Dec 2, 2022

    Ovarian Cancer Trial in United Kingdom (Olaparib, Cediranib, Paclitaxel)

    Active, not recruiting
    • Ovarian Cancer
    • Belfast, County Antrim, United Kingdom
    • +13 more
    Feb 22, 2022

    Ovarian Cancer, Chemotherapeutic Toxicity Trial in Evanston (Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin,

    Not yet recruiting
    • Ovarian Cancer
    • Chemotherapeutic Toxicity
    • Fasting Mimicking Diet (Xentigen by L'Nutra)
    • +3 more
    • Evanston, Illinois
      NorthShore University HealthSystem
    Jun 25, 2023

    Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)

    Not yet recruiting
    • Ovarian Cancer
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Jul 19, 2022

    Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

    Recruiting
    • Platinum-Resistant Fallopian Tube Carcinoma
    • +6 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    May 17, 2022

    Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

    Recruiting
    • Lung Neoplasm
    • +26 more
    • Boston, Massachusetts
    • +6 more
    Jun 23, 2022

    Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

    Not yet recruiting
    • Metastatic Cervical Cancer
    • (no location specified)
    Jan 31, 2023

    Limited Stage Small Cell Lung Cancer Trial in Shang'ai (chemo and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy)

    Not yet recruiting
    • Limited Stage Small Cell Lung Cancer
    • chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
    • Shang'ai, Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 8, 2022

    Thymic Carcinoma, NSCLC, Refractory Thoracic Tumors Trial in United States (VEGFR/PDGFR Dual Kinase Inhibitor X-82, Nivolumab)

    Active, not recruiting
    • Thymic Carcinoma
    • +3 more
    • VEGFR/PDGFR Dual Kinase Inhibitor X-82
    • Nivolumab
    • Palo Alto, California
    • +6 more
    Sep 21, 2022

    Molecular Subtyping of Extensive Stage Small Cell Lung Cancer

    Recruiting
    • SCLC,Extensive Stage
    • PD-(L)1 antibody immunotherapy
    • Beijing, Beijing, China
      Peking University Cancer Hospital & Institute
    Jul 3, 2023

    Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer Trial in Birmingham (Cohort 1: Dose Escalation, Cohort 2: Dose

    Terminated
    • Ovarian Cancer
    • Resistant BRCA Wild-Type Ovarian Cancer
    • Cohort 1: Dose Escalation
    • Cohort 2: Dose Escalation
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Apr 29, 2022

    Head and Neck Tumors Trial in Tainan, Taipei (SCB01A)

    Terminated
    • Head and Neck Neoplasms
    • Tainan, Taiwan
    • +3 more
    Jun 22, 2022